lumretuzumab
Lumretuzumab is a humanized monoclonal antibody that is under development for the treatment of various cancers. It is designed to target and inhibit the activity of the protein CD137, which is expressed on the surface of various cancer cells. CD137, also known as 4-1BB, plays a crucial role in the activation and proliferation of immune cells, including T cells and B cells.
The development of lumretuzumab is based on the observation that CD137 expression is often upregulated in
Clinical trials are currently underway to evaluate the safety and efficacy of lumretuzumab in combination with
Lumretuzumab is produced using recombinant DNA technology and is a humanized antibody, meaning it is derived
The development of lumretuzumab represents a novel approach in cancer immunotherapy, focusing on targeting the interaction